polatuzumab vedotin
roche
['pola']
wills: impact of systemic bridging therapy before cart.
residual disease, non-resp to bt=bad.
retrosp analysis, n=154.
successful debulking - better car outcome, irrespective of bt.
targeted, pola-based higher orr.
lower ldh, lower inflamm markers assoc to successful bt.
#17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.